抗体偶联药物

Shitara, K

Trastuzumab deruxtecan (T-DXd) vs ramucirumab   (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with   human epidermal growth factor receptor 2-positive (HER2+)   unresectable/metastatic gastric cancer (GC) or gastroesophageal junction   adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3   DESTINY-Gastric04 study.

Abstract #LBA4002

Oral Abstract Session

31 May 2025

3:24pm

Tolaney, SM

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P)   vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of   patients (pts) with human epidermal growth factor receptor 2–positive (HER2+)   advanced/metastatic breast cancer (a/mBC): Interim results from   DESTINY-Breast09.

Abstract #LBA1008

Oral Abstract Session

2 June 2025

7:30am

Dent, R

Exploratory biomarker analysis of trastuzumab   deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in   HER2-low/-ultralow, hormone receptor-positive (HR+) metastatic breast cancer   (mBC) in DESTINY-Breast06 (DB-06).

Abstract #1013

Oral Abstract Session

31 May 2025

3:23pm

Levy, BP

TROPION-Lung02: Datopotamab deruxtecan   (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy   (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer   (aNSCLC).

Abstract #8501

Oral Abstract Session

1 June 2025

8:12am

Waqar, SN

First-line (1L) datopotamab deruxtecan   (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung   cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).

Abstract #8521 

Poster Session

31 May 2025

1:30pm

肿瘤驱动因素和耐药性

Turner, NC

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for   the treatment of emergent ESR1 mutations during first-line (1L)   endocrine-based therapy (ET) and ahead of disease progression in patients   (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind   ctDNA-guided SERENA-6 trial.

Abstract #LBA4

Plenary Session

1 June 2025

2:41pm

Lu, S

Savolitinib (Savo) combined with osimertinib   (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and   MET-amplification (METamp) advanced NSCLC after disease progression (PD) on   EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI   study.

Abstract #LBA8505

Oral Abstract Session

1 June 2025

9:48am

Levy, BP

Efficacy and CNS results from a randomized   subset of the phase 2 SAVANNAH study comparing savolitinib (savo) +   osimertinib (osi) combination with savo + placebo (PBO).

Abstract #8513

Rapid Oral Abstract Session

2 June 2025

8:06am

Chaft JE

Neoadjuvant (neoadj) osimertinib (osi) ±   chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor   receptor-mutated (EGFRm) NSCLC: NeoADAURA.

Abstract #8001

Oral Abstract Session

2 June 2025

3:12pm

免疫肿瘤学与双特异性抗体

Janjigian, YY

Event-free survival in MATTERHORN: a   randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin,   oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable   gastric/gastroesophageal junction cancer (GC/GEJC).

Abstract #LBA5

Plenary Session

1 June 2025

3:13pm

Powles, T

Circulating tumor DNA (ctDNA) in patients with   muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab   (D) in NIAGARA

Abstract #4503

Oral Abstract Session

1 June 2025

10:45am

Reck, M

Associations of post-surgical MRD status with   neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in   patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

Abstract #8009

Rapid Oral Abstract Session

1 June 2025

4:30pm

Barbie, DA

Clinical and molecular characteristics of early   progressors (EPs) and long-term progression-free survivors (LTPs) from the   phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after   concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer   (LS-SCLC).

Abstract #8014

Rapid Oral Abstract Session

1 June 2025

5:12pm

Mayadev, J

Ultrasensitive detection and tracking of   circulating tumor DNA (ctDNA) and association with relapse and survival in   locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.

Abstract #5502

Oral Abstract Session

2 June 2025

8:48am

Westin, SN

Durvalumab plus carboplatin/paclitaxel followed   by durvalumab with or without olaparib as first-line treatment for   endometrial cancer: Longitudinal changes in circulating tumor DNA.

Abstract #5512

Rapid Oral Abstract Session

3 June 2025

8:30am

Erinjeri, JP

Outcomes by baseline tumor burden using the   6-and-12 score in EMERALD-1: a phase 3 study of durvalumab (D) ± bevacizumab   (B) with transarterial chemoembolization (TACE) in embolization-eligible   unresectable hepatocellular carcinoma (uHCC).

Abstract #4083
  Poster Session

31 May 2025

9:00am

Cascone, T

Neoadjuvant durvalumab (D) + chemotherapy (CT)   + novel anticancer agents and adjuvant D ± novel agents in resectable   non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.

Abstract #8046

Poster Session

31 May 2025

1:30pm

Zhou, J

First-line rilvegostomig (rilve) plus chemotherapy   (CTx) in advanced biliary tract cancer (BTC): Primary analysis of   GEMINI-Hepatobiliary substudy 2 Cohort A.

Abstract #4080

Poster Session

31 May 2025

9:00am

Xu, R

ARTEMIDE-Gastric01: a phase 3 randomized study   of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as   first-line (1L) treatment for locally advanced or metastatic HER2-positive   gastric or gastroesophageal junction cancer (GC/GEJC).

Abstract #TPS4204

Poster Session

31 May 2025

9:00am

Mathias, C

ARTEMIDE-Lung03: a phase 3, randomized,   double-blind, multicenter, global study of rilvegostomig or pembrolizumab in   combination with platinum-based chemotherapy as first-line treatment for   patients with metastatic non-squamous non-small-cell lung cancer whose tumors   express PD-L1.

Abstract #TPS8653

Poster Session

31 May 2025

1:30pm

细胞疗法

Yoo, C

RHEA-1: First-in-human (FIH) study of AZD9793,   a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive   (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC).

Abstract #TPS4215

Poster Session

31 May 2025

9:00am

Kim, TM

Safety and Efficacy of AZD0486, a CD19xCD3   T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Abstract #7046
  Poster Session

1 June 2025

9:00am

Shadman, M

TITANium: An open-label, global multicenter   Phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided   tri-specific T-cell engager (TCE), in patients (pts) with relapsed or   refractory (r/r) B-cell malignancies.

Abstract #TPS7091

Poster Session

1 June 2025

9:00am

Le Gouill, S

SOUNDTRACK-E: A Phase 1/2 Open-label   Multicenter Study to Evaluate the Safety and Efficacy of AZD0486 Monotherapy   or Combination Therapy in Patients With Mature B-cell Malignancies.

Abstract #TPS7083

Poster Session

1 June 2025

9:00am

罕见病药物

Chen, AP

Efficacy and safety of selumetinib in adults   with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform   neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a Phase 3,   international, randomized, placebo-controlled study.

Abstract #3014

Rapid Oral Abstract Session

2 June 2025

8:00am